Primary candidates for GLP-1 therapy include: Patients with type 2 diabetes and inadequate glycemic control despite metformin therapy Individuals with type 2 diabetes and established atherosclerotic cardiovascular disease Patients with type 2 diabetes and multiple cardiovascular risk factors (hypertension, dyslipidemia, obesity) Adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with weight-related comorbidities Patients with metabolic syndrome who have not achieved adequate risk factor control with lifestyle modification For patients with dyslipidemia, GLP-1 agents may be particularly valuable when combined with statin therapy in those who have not reached LDL-C goals or who have persistent hypertriglyceridemia despite statin treatment
Knowing the combination remains effective and well-tolerated over 104 weeks provides the kind of reassurance that 40-week data alone cannot
Assessments Baseline clinical and treatment characteristics including age, Eastern Cooperative Oncology Group Performance Status, comorbidities, use of antithrombotic medication, initial prostate-specific antigen (PSA) level, stage of prostate cancer, Gleason score, radiotherapy volume, treatment modality, use of androgen deprivation therapy, and dose-volume histogram (DVH) parameters of the rectal wall were collected
Realistic Weight Loss Goals One of the most important parts of any medical weight loss journey is setting realistic expectations
Although the body can produce small amounts naturally, dietary intake may not always be sufficient, especially for vegetarians or people with specific health conditions
What this can look like: observing hormone patterns across cycles identifying ovulation patterns over time comparing cycles before and during GLP-1 use noticing trends, not just single changes Important context: Tracking is observational , not diagnostic Hormonal changes can have multiple causes GLP-1 is one of several factors that may influence patterns The goal is not to explain why but to help you capture whats changing